OTO-201
Phase 3Small molecule
OTO-201 is one of 22 small molecule programs targeting Otitis Externa. It is currently in Phase 3.
2
Indications
7
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Otitis Media
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Biaxin
AbbVieApproved
Keflex
Eli LillyApproved
Levaquin
WWim Janssens
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Decadron
AAspen Global Incorporated
Approved
Ketek
SanofiPhase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Amoxycillin
MMenzies School of Health Research
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Treatment3 trials
Otitis media1 trial
MPA1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OTO-201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- OOtonomy, Inc.